Adma Biologics Inc(ADMA) Price Forecast & Company Analysis. P/E · Dividend · Earnings · Price Target · RSI · MACD | US Stocks Today
Full metrics table
| Index | RUT | P/E | 16.01 | EPS (ttm) | 0.7 | Insider Own | 4.3% | Shs Outstand | 225.4M | Perf Week | 2.45% |
| Market Cap | 2.53B | Forward P/E | 11.96 | EPS next Y | 18.41% | Insider Trans | 0.33% | Shs Float | 214.3M | Perf Month | 13.25% |
| Enterprise Value | 2.59B | PEG | 0.54 | EPS next Q | 0.2 | Inst Own | 89.59% | Short Float | 9.11% | Perf Quarter | 30.1% |
| Income | 0.17B | P/S | 4.93 | EPS this Y | 21.3% | Inst Trans | -4.13% | Short Ratio | 7.39 | Perf Half Y | 6.42% |
| Sales | 0.51B | P/B | 6.23 | EPS next 5Y | 22.25% | ROA | 27.19% | Short Interest | 19.53M | Perf YTD | -38.16% |
| Book/sh | 1.81 | P/C | 18.57 | EPS past 3/5Y | - | ROE | 41.9% | 52W High | -44.86% ($20.46) | Perf Year | -27.55% |
| Cash/sh | 0.61 | P/FCF | 21.69 | Sales past 3/5Y | 49.05% 64.6% | ROIC | 27.83% | 52W Low | 56.45% ($7.21) | Perf 3Y | 240.79% |
| Dividend Est. | - | EV/EBITDA | 11.57 | EPS Y/Y TTM | -18.53% | Gross Margin | 64.67% | Volatility(W/M) | 3.03% 3.49% | Perf 5Y | 741.79% |
| Dividend TTM | - | EV/Sales | 5.06 | Sales Y/Y TTM | 8.04% | Oper. Margin | 42.26% | ATR (14) | 0.36 | Perf 10Y | 92.16% |
| Dividend Ex-Date | - | Quick Ratio | 3.81 | EPS Q/Q | 19.33% | Profit Margin | 32.98% | RSI (14) | 66.77 | Recom | 1.33 |
| Dividend Gr. 3/5Y | - | Current Ratio | 6.97 | Sales Q/Q | 1.98% | SMA20 | 6.68% ($10.57) | Beta | 0.67 | Target Price | $18.67 |
| Payout | - | Debt/Eq | 0.5 | Earnings | 2026/11/4 | SMA50 | 13.57% ($9.93) | Rel Volume | 1.01 | Prev Close | $11.17 |
| Employees | 647 | LT Debt/Eq | 0.49 | EPS/Sales Surpr. | 0.98% -0.76% | SMA200 | 2.34% ($11.02) | Avg Volume(3M) | 2.64M | Price | $11.28 |
| IPO | 2013/10/17 | Option/Short | Yes/Yes | Trades | 12647 | Volume | 2,664,532 | Change | 0.98% |
🩸 This is a U.S. biotech company that develops and manufactures plasma-derived immunoglobulin therapies. It produces immunoglobulin treatments for patients with immune deficiencies and other conditions, and operates its own plasma collection centers to secure source plasma, giving it a vertically integrated business structure. The company is an established, commercial-stage plasma biologics player that has integrated the full process from plasma collection through to immunoglobulin manufacturing.
Over the past 1 year, roughly in the middle
45% below its 1-year high.
Traded about as much as usual. That is 101% of its average volume.
Next earnings report: November 4
6 days to go.
ADMA makes money exceptionally well
Of every $100 in sales, $42.26 is kept as operating profit.
Tap to view numbers
Earnings are growing steadily
Earnings are expected to grow by +21.3% this year.
Tap to view numbers
The price is about the industry average
Counting its debt, for $100 of yearly operating cash you would pay $1,157. Peers typically go for $4,561. Compared with its own 2-year average, it is 28% cheaper now.
Tap to view numbers
Results came in about as expected
Mixed beats and misses
Tap to view numbers
The outlook is positive
Analyst sentiment is Strong Buy.
Tap to view numbers
Holding long would have paid off
Bought 5 years ago, your return today would be +741.8%. The S&P 500 did +69% over the same period.
Tap to view numbers
No dividend
It reinvests profits in the business instead of paying dividends.
Ownership looks stable
Institutions hold 89.6%.
Tap to view numbers
Multiple ETFs hold this stock, but only a sliver
Buying this ETF gives you exposure to this stock as well.
It ranks #81 of 594 in the industry
Based on market cap of $3B.
RXRX#79 Recursion Pharmaceuticals Inc $3B PER - 
ZLAB#80 Zai Lab Limited ADR $3B PER - ADMA#81 Adma Biologics Inc $3B PER 16.0 
NAMS#82 NewAmsterdam Pharma Company NV $3B PER - 
FTRE#83 Fortrea Holdings Inc $2B PER - 
FAQ
What kind of company is ADMA?
ADMA belongs to the Healthcare sector and operates in the Biotechnology industry.
What is the market cap of ADMA?
The market cap of ADMA is approximately $2.5B, ranking 1,883 within its sector.
What is the P/E ratio of ADMA?
ADMA has a P/E ratio of approximately 16.0x, which can be used to assess its valuation relative to the Healthcare sector average.
What is the 52-week high and low for ADMA?
ADMA has recorded a 52-week high of $20.46 and a low of $7.21.
